ClinicalTrials.gg
RecruitingNCT07185997Updated Nov 2, 2026

Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations

A Phase 3 interventional study of Firmonertinib and EGFR-TKI inhibitor based on investigator's choice in Non-Small-Cell Lung Cancer, Metastatic Non-Small-Cell Lung Cancer and Advanced Non-Small-Cell Lung Cancer, sponsored by ArriVent BioPharma, Inc.. Recruiting at 141 sites in 17 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-02.

Sponsored by ArriVent BioPharma, Inc. · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Started Dec 2025; still recruiting 10 months later.
Updated Nov 2, 2026Eligibility revised23 sites addedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
480
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 41 studies testing aflutinib in Carcinoma, Non-Small-Cell Lung — 31 open to participants now, 34 under way, 5 of them phase 3. aflutinib · Carcinoma, Non-Small-Cell Lung.

Planned enrollment
2nd of 41
480 · median 60
Started
2025
with 6 others
Phase 3
5 of 41
3 open now
Primary completion
2029-02
later than 29 of 33 live
Registered
29th of 41
by date
Lead sponsor
3 of 41
ArriVent BioPharma, Inc.

Among the 41 studies testing aflutinib in Carcinoma, Non-Small-Cell Lung, this one is the 2nd largest by planned enrollment, is one of 7 that started in 2025, is one of 5 in phase 3, reaches primary completion later than 29 of the 33 other live ones, and was the 29th registered.

Carcinoma, Non-Small-Cell Lung

7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,837 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

31 of the 41 studies testing aflutinib in Carcinoma, Non-Small-Cell Lung are open now, in 12 countries. Recruiting first, the newest first:

25 more — sign in →

By country, each count listing its studies:

All 31 open studies →

About aflutinib

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 1,326 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 225 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 41 studies testing aflutinib in Carcinoma, Non-Small-Cell Lung, or all of them as a file.
02

Study summary

Global, Phase 3, randomized, multicenter, open-label study evaluating the efficacy and safety of firmonertinib at a dose level of 240 mg QD compared to investigator's choice of osimertinib (80 mg QD) or afatinib (40 mg QD) in participants who have locally advanced or metastatic NSCLC with EGFR PACC mutations, and who have not received any prior therapy for advanced disease. Participants will be randomized in a 1:1 ratio to treatment with firmonertinib or osimertinib or afatinib and will take the assigned dose daily.

03

Conditions studied

  • Non-Small-Cell Lung Cancer
  • Metastatic Non-Small-Cell Lung Cancer
  • Advanced Non-Small-Cell Lung Cancer
  • EGFR P-Loop and Alpha C-Helix Compressing
  • EGFR PACC
  • EGFR Uncommon Mutations

Keywords

  • Non-Small Cell Lung Cancer (NSCLC)
  • PACC
  • Firmonertinib
  • Furmonertinib
  • AST2818
  • FURMO-006
  • Drug-Therapy
  • Metastatic Non-Small Cell Lung Cancer
  • Advanced Non-Small Cell Lung Cancer
  • NSCLC
  • Osimertinib
  • Afatinib
  • metastatic NSCLC first-line treatment
  • Carcinoma NSCLC
  • Respiratory tract neoplasms
  • Bronchial Neoplasms
  • Protein Kinase Inhibitors
  • tyrosine kinase inhibitor (TKI)
  • Alflutinib
  • Lung neoplasms
  • EGFR kinase domain mutations
  • EGFR activating mutation
  • EGFR mutation of unknown significance
  • Non-classical EGFR mutation
  • EGFR uncommon mutations
  • EGFR atypical mutations
  • EGFR
  • G719X
  • S7681
  • E709X
  • E709_T710delinsD
  • G779F
  • L747X
  • V774M
  • L747P/S
  • R776C/H
  • G724S
  • E736K
  • 1740_K745dup
  • N771G
  • K757M/R
  • V769L/M
04

Who can participate

The criteria were revised on the registry on Oct 14, 2026. See what changed

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Eligibility Criteria:

  • or cytologically documented, locally advanced or Non-Small Cell Lung Cancer (NSCLC) not amenable to curative surgery or radiotherapy.
  • Documented results of the presence of an Epidermal Growth Factor Receptor (EGFR) PACC mutation in tumor tissue or blood from local testing.
  • No prior systemic anticancer therapy regimens received for locally advanced or metastatic Non-Small Cell Lung Cancer (NSCLC) including prior treatment with any Epidermal Growth Factor Receptor (EGFR)-targeting agents (e.g., previous (EGFR) TKIs, monoclonal antibodies, or bispecific antibodies).
  • Patients who have received prior and/or adjuvant chemotherapy, immunotherapy, or chemo radiotherapy for non-metastatic disease must have experienced a treatment free interval of at least 12 months.
  • Patients with asymptomatic are eligible.
  • List of eligible PACC mutations:

E709X, E709A, E709H, E709V, E709K E709_T710delinsD, E709_T710delinsA, E709_T710delinsG, L718M, L718P, L718Q, L718V, G719X, G719A, G719C, G719D, G719S, G724S, E736K, I740_K745dup, I740_K745dupIPVAIK, I744_K745insKIPVAI, L747P, L747S, K757M, K757R, V765L, S768I, S768_V769delinsIL, S768_V769delinsIM, S768_V769delinsPL, V769L, V769M, N771G, H773_V774delinsLM, V774M, R776C, R776H, G779F, L792H, G796S, T854A, T854S, T854I, A647T, R675W, S768C, A755D, A750_I759delinsPN, T751_I759delinsN

Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
480 participants (estimated)

Study arms

  • Experimental
    Firmonertinib 240 mg

    Drug: Firmonertinib

  • Active comparator
    EGFR-TKI inhibitor osimertinib or afatinib based on investigator's choice

    Drug: EGFR-TKI inhibitor based on investigator's choice

Interventions

  • 240 mg oral, daily firmonertinib tablet

    Also known as: AST2818

  • DrugEGFR-TKI inhibitor based on investigator's choice

    osimertinib 80 mg oral, daily tablet OR afatinib 40 mg oral, daily tablet

This study also gives Osimertinib. No intervention listed here names it: that was found by reading the record.

06

What researchers measure

Primary outcomes

  1. Progression Free Survival (PFS) determined by blinded independent central review (BICR)

    PFS is defined as the time from randomization to the first occurrence of disease progression as determined by BICR using RECIST v1.1, or death from any cause, whichever occurs first.

    Time frame: Until progression or death, assessed up to approximately 4 years

  2. Confirmed overall response rate (ORR) as determined by BICR

    Confirmed ORR is defined as the percentage of participants with a confirmed CR or PR based on BICR assessment relative to the total number of participants.

    Time frame: Until progression or death, assessed up to approximately 3 years

Secondary outcomes

  1. Overall survival (OS)

    OS is defined as the time from randomization to death from any cause.

    Time frame: Until death, assessed up to approximately 5 years

  2. Investigator-assessed PFS

    Investigator-assessed PFS is defined as the time from randomization to the first documented disease progression or death, whichever occurs first, based on investigator assessment per RECIST v1.1.

    Time frame: Until progression or death, assessed up to approximately 4 years

  3. Investigator-assessed confirmed ORR

    Investigator-assessed confirmed ORR is defined as the percentage of participants with a confirmed CR or PR based on investigator assessment relative to the total number of participants.

    Time frame: Until progression or death, assessed up to approximately 3 years

  4. Duration of response (DOR)

    DOR is defined as the time from first documented evidence of CR or PR until the first documented evidence of disease progression or death, whichever occurs first.

    Time frame: Until progression or death, assessed up to approximately 4 years

  5. Time to second Progression-free survival (PFS2)

    PFS2 is defined as the time from randomization to second progression (ie, earliest of the subsequent progression events after initiation of a new anti-cancer treatment), or death from any cause, whichever occurs first.

    Time frame: Assessed up to approximately 5 years

  6. Incidence and severity of adverse events (AEs), as a measure of safety and tolerability of firmonertinib

    An AE is defined as any unfavorable or unintended medical occurrence in a trial participant administered a pharmaceutical product, regardless of causal attribution.

    Time frame: Assessed up to approximately 5 years

  7. Change from baseline in safety-related clinical laboratory test results

    Safety-related laboratory parameters include absolute neutrophil count, hemoglobin, platelet count, albumin, blood urea nitrogen (BUN), chloride, creatinine, potassium, sodium, alkaline phosphatase (ALP), alanine aminotransferase (ALT); aspartate aminotransferase (AST), total bilirubin. Each parameter is measured using its standard unit. Changes in participants' laboratory test values are evaluated by comparing baseline (pre-treatment) results with those obtained at prespecified time points during or following the treatment.

    Time frame: Assessed up to approximately 5 years

07

Study locations

141 of 141 sites recruiting

Showing the first 100 of 141 sites across 17 countries. Choose a country and city above to see the rest.

08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2025 (actual). Primary completion is estimated for Feb 2029, 38 months after the start.

Of 315 industry-sponsored phase 3 interventional studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 27 and three quarters within 57. This study's planned 38 months is close to that.

Counting every sponsor, half of 424 studies reached it within 45 months; a quarter within 30 and three quarters within 69.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 15, 2025
First posted
Sep 22, 2025
StartActual
Dec 17, 2025
Primary completionEst.
Feb 2029
CompletionEst.
Dec 2030
Last update
Nov 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
23 sites added
Show 23 added (21 China, 1 United States, 1 Canada)
  • Columbia University Medical Center · New York, United States
  • University of Alberta - Cross Cancer Institute (CCI) · Edmonton, Canada
  • Anhui Provincial Hospital · Hefei, China
  • Peking University Cancer Hospital (PKUCH)/Beijing Cancer Hospital · Beijing, China
  • The First Affiliated Hospital of Chongqing Medical University · Chongqing, China
  • Fujian Cancer Hospital · Fuzhou, China
  • The First Affiliated Hospital, Sun Yat-sen University · Guangzhou, China
  • Nanfang Hospital, Southern Medical University · Guangzhou, China
  • Guangxi Medical University Cancer Hospital · Nanning, China
  • Henan Cancer Center · Zhengzhou, China
  • Xiangya Hospital of Central South University · Changsha, China
  • Hunan Cancer Hospital · Changsha, China
  • The First Hospital of China Medical University · Shenyang, China
  • Cancer hospital of Dalian university of technology · Shenyang, China
  • Jinan Central Hospital · Jinan, China
  • Linyi Cancer Hospital · Linyi, China
  • Shanghai Geriatric Medical Center · Shanghai, China
  • Shanghai Pulmonary Hospital · Shanghai, China
  • West China Hospital of Sichuan University · Chengdu, China
  • Yibin Second People's Hospital · Yibin, China
  • The First Affiliated Hospital,Zhejiang University School of Medicine · Hangzhou, China
  • Cancer Hospital Chinese Academy of Medical Sciences · Beijing, China
  • The Second Hospital of Dalian Medical University · Dalian, China
across 2 updates, Oct 14, 2026 – Nov 2, 2026
Eligibility
2 criteria added
What changed in the criteria
  • AddedList of eligible PACC mutations:
  • AddedE709X, E709A, E709H, E709V, E709K E709_T710delinsD, E709_T710delinsA, E709_T710delinsG, L718M, L718P, L718Q, L718V, G719X, G719A, G719C, G719D, G719S, G724S, E736K, I740_K745dup, I740_K745dupIPVAIK, I744_K745insKIPVAI, L747P, L747S, K757M, K757R, V765L, S768I, S768_V769delinsIL, S768_V769delinsIM, S768_V769delinsPL, V769L, V769M, N771G, H773_V774delinsLM, V774M, R776C, R776H, G779F, L792H, G796S, T854A, T854S, T854I, A647T, R675W, S768C, A755D, A750_I759delinsPN, T751_I759delinsN
Oct 14, 2026
Show all 2 updates
  1. Nov 2, 2026
    2 sites added
    Show 2 added (2 China)
    • Cancer Hospital Chinese Academy of Medical Sciences · Beijing, China
    • The Second Hospital of Dalian Medical University · Dalian, China
  2. Oct 14, 2026
    21 sites added
    Show 21 added (19 China, 1 United States, 1 Canada)
    • Columbia University Medical Center · New York, United States
    • University of Alberta - Cross Cancer Institute (CCI) · Edmonton, Canada
    • Anhui Provincial Hospital · Hefei, China
    • Peking University Cancer Hospital (PKUCH)/Beijing Cancer Hospital · Beijing, China
    • The First Affiliated Hospital of Chongqing Medical University · Chongqing, China
    • Fujian Cancer Hospital · Fuzhou, China
    • The First Affiliated Hospital, Sun Yat-sen University · Guangzhou, China
    • Nanfang Hospital, Southern Medical University · Guangzhou, China
    • Guangxi Medical University Cancer Hospital · Nanning, China
    • Henan Cancer Center · Zhengzhou, China
    • Xiangya Hospital of Central South University · Changsha, China
    • Hunan Cancer Hospital · Changsha, China
    • The First Hospital of China Medical University · Shenyang, China
    • Cancer hospital of Dalian university of technology · Shenyang, China
    • Jinan Central Hospital · Jinan, China
    • Linyi Cancer Hospital · Linyi, China
    • Shanghai Geriatric Medical Center · Shanghai, China
    • Shanghai Pulmonary Hospital · Shanghai, China
    • West China Hospital of Sichuan University · Chengdu, China
    • Yibin Second People's Hospital · Yibin, China
    • The First Affiliated Hospital,Zhejiang University School of Medicine · Hangzhou, China
    Eligibility 2 criteria added
    What changed in the criteria
    • AddedList of eligible PACC mutations:
    • AddedE709X, E709A, E709H, E709V, E709K E709_T710delinsD, E709_T710delinsA, E709_T710delinsG, L718M, L718P, L718Q, L718V, G719X, G719A, G719C, G719D, G719S, G724S, E736K, I740_K745dup, I740_K745dupIPVAIK, I744_K745insKIPVAI, L747P, L747S, K757M, K757R, V765L, S768I, S768_V769delinsIL, S768_V769delinsIM, S768_V769delinsPL, V769L, V769M, N771G, H773_V774delinsLM, V774M, R776C, R776H, G779F, L792H, G796S, T854A, T854S, T854I, A647T, R675W, S768C, A755D, A750_I759delinsPN, T751_I759delinsN
    + 2 other changes: verification date and conditions

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07185997
Lead sponsor
ArriVent BioPharma, Inc.
Responsible party
Sponsor
First posted
Sep 22, 2025
Start date
Dec 17, 2025
Primary completion
Feb 2029 (estimated)
Completion
Dec 2030 (estimated)
Last update
Nov 2, 2026

Study contacts

Clinical Trials
Contact
FURMO006CT@arrivent.com
(888) 622-2827
Jamuna Thimmarayappa
study director · ArriVent BioPharm

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Aflutinib

Start the discussion